Copyright © 2014 JPSBR Publications
Powered by Opus
Volume 7, Issue 4
Available online on 1 Aug 2017
ISSN 2277-3681
J Pharm Sci Bioscientific Res. 2017; 7(4):
Formulation Development and Evaluation of saxagliptin as mouth dissolving tablet
Nancy Dalsania, Hardeep Banwait, Sahjesh Rathi, Pragnesh Patni
Simultaneous RP-HPLC Determination of Sparfloxacin and Dexamethasone in Combined Dosage Form
Kunjal L. Vegad*, Noopur H. Dani, Dhwani A. Shah, Ekta D. Patel, Yogesh K. patel, Chhaya R. Macwana
Effectiveness of DPP-IV Inhibitors versus Sulphonylureas in Management of Uncontrolled Type-II Diabetes
Mellitus- A Comparative Study
M R Patel*, P D Sachdeva, M S Saiyed
Comparative Study for the Development and Validation of Analytical Methods for Simultaneous Estimation of
Paracetamol and Ondansetron in Lupisetron-Plus, Vomikind-Plus and Myset-Plus Tablet Dosage Form
Ekta D. Patel, Pratik A. Patel , Dhwani A. Shah , Kunjal L. Vegad , Yogesh K. Patel , Chhaya R. Macwana
Analytical Method Development and Validation for Simultaneous Estimation of Oxycodone Hydrochloride and
Naltrexone Hydrochloride in Synthetic Mixture
Megha Shah, Saurabh V. Jaiswal-Choudhary*, Rashmi Singh
Chiari Syndrome
Swati Kansara*, Debanjali Chetterji, Nupur Thakur
ABSTRACT:
The objective is preparation and evaluation of mouth dissolving tablet for saxaglitin salt. Mouth Dissolving tablets
of Saxagliptin hydrochoride were successfully formulated by employing direct compression method. Evaluation
parameters like hardness and friability indicated good mechanical resistance of the tablets for all the formulations.
Percentage weight variation and drug content uniformity were found to be within the approved range for all the
formulations. The in-vitro release studies showed 78% of drug release in less than 5 minutes. Overall, in the
formulations prepared by direct compression method, F8 which contain 15% CCS as Superdisintegrant releases
98.9 % drug in just 10 minutes was found to be best formulation. Taste masking has been done with Beta
Cyclodextrin (1:1) ratio using kneading method. From the factorial batches. SXG8 gives faster release and
Disintegration than the other formulation with optimum concentration of CCS. So SXG8 was optimized formulation
having disintegration time is about 52 seconds. The stability studies carried out at 400C and 75 % RH for 1 month
showed no significant change in drug content, In-vitro disintegration time and drug release profile revealing
excellent stability of the formulated formulations.
KEY WORDS: Mouth Dissolving tablets, Saxagliptin, Beta Cyclodextrin, Taste masking agent, Croscarmellose
sodium, Superdisintegrant.
![[x]](JPSBR_Vol_7_Issue_1_htm_files/close.png "Close")
ABSTRACT:
A precise, simple, accurate and selective method was developed and validate for estimation of SPARFLOXACIN and
DEXAMETHASONE in laboratory prepared mixtures as well as in combined dosage form. Reversed phase high
performance liquid chromatographic (RP-HPLC) method was developed for routine quantification of Sparfloxacin
and Dexamethasone in laboratory prepared mixtures as well as in combined dosage form. Chromatographic
separation was achieved on a BDS hypersil C18 (5μ, 250 x 4.6 mm) utilizing mobile phase of 0.1% Potassium
dihydrogen phosphate: Acetonitrile (60:40 v/v) at a flow rate of 1 mL/min with UV detection at 247 nm. The
method has been validated for linearity, accuracy and precision. In RP-HPLC method, the calibration graphs were
linear in the concentration range of 6-36 μg/mL for Sparfloxacin and 2-12 μg/mL for Dexamethasone with mean
recoveries of 99.91% and 99.94% for Sparfloxacin and Dexamethasone respectively. The results obtained by RP-
HPLC methods are rapid, accurate and precise.
KEY WORDS: RP-HPLC, Sparfloxacin, Dexamethasone, Simultaneous estimation
ABSTRACT:
Objective: To evaluate effectiveness and tolerability of DPP-IV inhibitors versus Sulphonylureas in treatment of
Type-II Diabetes Mellitus (T2DM) patients, uncontrolled with Metformin alone. Methods: 50 patients suffering
from T2DM and receiving treatment with Metformin were recruited for the study based on inclusion and exclusion
criteria after obtaining their informed consent. Recruited patients were randomly prescribed combination of
Sulphonylurea + Metformin and DPP-IV inhibitors + Metformin. Blood glucose levels were checked every month
and HbA1c was checked at the end of three months treatment. Results and Discussion: Sulphonylureas as well as
DPP-IV inhibitors when given in combination with Metformin reduced RBG, FBG and PP2BG after one month
treatment, without any significant difference as compared with baseline values. Comparing the PP2BG and HbA1c
values in both treatment groups after three months, the difference was found to be statistically significant. Also
incidence of adverse effects was observed to be higher in Sulphonylurea + Metformin group. Conclusion: Results of
the study lead to the conclusion that both treatment groups are equally effective in management of T2DM
uncontrolled with Metformin alone. However, looking at tolerability aspect DPP-IV inhibitors seem to be more safe
and tolerable as compared to Sulphonylureas.
KEYWORDS: DPP-IV Inhibitors, Metformin, Type-2 Diabetes Mellitus, Sulphonylureas
ABSTRACT:
A newer, simple, rapid, accurate, precise and sensitive method was developed and validated for estimation of
Oxycodone Hydrochloride (OXY) and Naltrexone H
ydrochloride (NAL) in Synthetic Mixture. The method employed
was First order derivative Concentration range of 10-30 μg/ml for Oxycodone Hydrochloride and 1.2-3.6 μg/ml for
Naltrexone Hydrochloride for the proposed method. First order Derivative method, wh
erein wavelengths selected
were 262.93nm (ZCP of Naltrexone Hydrochloride) for Oxycodone Hydrochloride and 238.62 nm (ZCP of
Oxycodone Hydrochloride) for Naltrexone Hydrochloride. Area under Curve Method was another method was
employed for Simultaneous Est
imation of Oxycodone Hydrochloride and Naltrexone Hydrochloride in Synthetic
mixture. The Concentration range was selected for estimation of Oxycodone Hydrochloride was 10-30 μg/ml and for
Naltrexone Hydrochloride was 1.2-3.6 μg/ml for the AUC Method. For Area under Curve Method, the wavelength
ranges selected was 244-264 nm for OXY and NAL at 270-290 nm for estimation of Oxycodone Hydrochloride and
Naltrexone Hydrochloride respectively. In HPLC method, Enable C18 (250 x 4.6 mm, 5 μm) column was used as
sta
tionary phase and Acetonitrile: Water are in the ratio of 60:40, (v/v) and pH was adjusted to 5.0 with ortho
phosphoric acid) as mobile phase was used. The flow rate was 0.8 ml/min and both drugs were detection was
carried out at 286.9 nm. The retention ti
me for OXY and NAL was found at 2.136 min and 5.485 min. respectively.
Linearity of OXY at 10-30 μg/ml and NAL at 1.2-3.6 μg/ml.
KEY WORDS:
Oxycodone Hydrochloride (OXY) and Naltrexone Hydrochloride (NAL), First Order derivative method,
ZCP (Zero Cross point), Area under Curve Method (AUC), RP-HPLC.
ABSTRACT:
World Health organization defined rare diseases as prevalence of 1 or less per 1000 population. Rare diseases are
usually genetic and because of this reason these are chronic also. Budd–Chiari syndrome is one of the rare disease.
Budd-Chiari syndrome is a congestive hepatopathy caused by blockage of hepatic veins. It involves obstruction of
hepatic venous outflow tracts at various levels from small hepatic veins to the inferior vena cava and is the result
of thrombosis or its fibrous sequelae. This rare disease is usually caused by multiple concurrent factors, including
acquired and inherited thrombophilia. Half of the patients with primary Budd–Chiari syndrome are affected with a
myeloproliferative disease.
KEY WORDS:
Budd Chiari syndrome; Etiology; Epidemiology; Manifestation; Diagnosis; Treatment.
ABSTRACT:
A RP-HPLC method is developed and validated for comparison of simultaneous estimation of paracetamol and
ondansetron in Lupisetron-Plus, Vomikind-Plus and Myset-Plus Tablet Dosage Form. Paracetamol(PCM) act by
inhibition of cyclooxygenase (COX) and has specific selectivity for COX-2. Paracetamol use for headache, backache
and fever. Ondansetron(OND) acct as selective serotonin 5-HT2 receptor antagonist use in nausea, nausea and
vomiting due to chemotherapy. The chromatographic separation was done by using BDS hypersil C18 column (250
mm, 4.6 mm i.d., 5 μm) using stationary phase & Phosphate Buffer pH 5.5 : ACN (40:60 V/V) at ambient
temperature. The detection wavelength was at 297 nm. The average retention time for PCM and OND were found
to be 3.727 and 6.037min. The method was validated in terms of linearity, range, accuracy, precision, limit of
detection (LOD) and limit of Quantitation (LOQ). Linearity for PCM and OND were found in the concentration
range from 62.5-187.5 μg/ml (r2 = 0.999) and 0.5-1.5 μg/ml (r2 = 0.988). Accuracy of the method was studied by
the recovery studies at three different levels 80%, 100% and 120% level. The percentage recovery was found to be
within the limits of acceptance criteria with average recovery of 99.62 – 99.87% for PCM and 100.32 – 100.62% for
OND. The high precision of proposed method is confirmed by % RSD below 2.0 for repeatability. Thus the proposed
method was successfully applied for simultaneous estimation of paracetamol and Ondansetron from Lupisetron-
Plus tablet dosage form for routine analysis.
KEY WORDS: Paracetamol, Ondansetron, Linearity, Accuracy, Lupisetron-Plus
